Kornimate/medical-research-clean huggingface dataset:
healthy living in overweight and obese adolescents asge-fabes program in development of formats

Conditions: Healthy Lifestyle Behaviors; Overweight Adolescents; Obese Adolescents

Summary: the aim of this project is to develop multiple behavioral strategies for the prevention of obesity in adolescents. asge-fabes \[adolescent health promotion physical activity, physical activity of overweight and obese youth of nutrition, stress management\] program,to evaluate its effects on nutrition and mental health. program overweight and obeseadolescents to lose weight in a healthy way, healthy lifestyle behaviors make healthy choices, nutritional and physical activity knowledgecognitive and it aims to gain behavioral skills. in the study, "pretest-posttest in randomized groupswith control group, with repeated measures \& quot; experimental design type is used. the sample of the research,250 (125-experiment, 125-control) constituted an overweight and obese adolescent.

the aim of this project is to evaluate the impact of asge-fabes program for the prevention of obesity in adolescents on physical activity, nutritional and mental health of overweight and obese adolescents. the program aims at promoting cognitive and behavioral skills for overweight and obese adolescents to lose weight in a healthy way, to promote healthy lifestyle behaviors, to make healthy choices, to increase their knowledge of nutrition and physical activity, to assume their own health responsibilities and to cope with stress. in the study, quot;experimental design type with randomized groups, pretest-posttest control group, repeated measurement\&quot; was used. the sample of the study consisted of 250 overweight and obese adolescents studying in the 6th grade of 10 secondary schools in şişli district of istanbul. the data of the study were collected using with socio-demographic characteristics form,adolescent nutrition information scale,adolescent physical activity information scale, adolescent lifestyle scale, adolescent healthy lifestyle choose scale, beck anxiety scale, daily food consumption form and beverage consumption form.the data were collected before the application, at the first week after the application, and at the sixth and 12th months. descriptive statistical tests, pearson chi-square tests, t-test in similar groups, repeated measures anova, and cohen\&#39;s effect size tests were used in the analysis of the study. there was no significant difference between the experimental and control groups in terms of the descriptive characteristics, behavioral and cognitive variables of adolescents.

Eligibility criteria:
inclusion criteria: * being overweight or obese * 11-12 age range * children asked by their parents to participate in the study exclusion criteria: * having a genetic disease * normal weight * mental disability

Keywords: adolescent health nursing obesity school health healthy lifestyle behaviors
a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx in imrt for head and neck cancer

Conditions: Head and Neck Cancer; Radiotherapy; Oropharynx Abnormality; Radiotherapy; Adverse Effect

Summary: the investigators tries a new method to delineating the oral cavity, oropharynx, larynx and hypopharynx, and use the head-and-neck region to test whether the method can to create a good imrt plan, and alleviate the oral radiation injury, reduce the incidence of adverse reactions.

purpose: to assess the dosimetric effect of new delineation approach for oral cavity, oropharynx, larynx and hypopharynx in intensity-modulated radiotherapy(imrt) treatment planning for head and neck cancer. methods: twenty head and neck cancer patients were treated by imrt. target volumes and several organs at risk were delineated with corvus6．3 treatment planning system. an investigative imrt plan was generated based on a standard treatment planning protocol, but used a new delineation approach for oral cavity, oropharynx, larynx and hypopharynx. plans were exported to treatment planning system for quantitative analysis of dose volume parameters. variables assessed included: maximum oral cavity, oropharynx, larynx and hypopharynx dose, equivalent uniform dose of the oral cavity, oropharynx, larynx and hypopharynx (eud), mean oral cavity, oropharynx, larynx and hypopharynx dose, mean organs at risks (oars) doses, and dose homogeneity inside the target volumes. .

Eligibility criteria:
inclusion criteria: - patients with previously untreated of the head and neck cancer who received definitive imrt at our institution exclusion criteria: -

Keywords: oropharynx dosimetric parameters intensity-modulated radiation treatment（imrt） head and neck cancer radiotherapy
a study comparing the efficacy, safety and tolerability of latanoprost 75, 100 and 125 ug/ml to xalatan in the treatment of primary open-angle glaucoma and ocular hypertension

Conditions: Primary Open Angle Glaucoma; Ocular Hypertension

Summary: the primary objective of this study was to compare the change in intraocular pressure (iop) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.


Eligibility criteria:
inclusion criteria: * male or female, 18 years of age or older. * primary open angle glaucoma (poag) or ocular hypertension (oht) requiring unilateral or bilateral administration of intraocular pressure (iop) lowering treatment, including patients who were naïve to iop lowering treatment. * iop between ≥ 24 mmhg and ≤ 36 mmhg in at least one eye at the 8 am time point at baseline/randomization. exclusion criteria: * closed/barely open anterior chamber angle or a history of acute angle closure. * a history of discontinued prostaglandin iop lowering treatment, unless the reason for discontinuation was participation in a clinical study. * ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months prior to the screening visit. * use or anticipated requirement during the study of any topical medication that was known to affect iop. * anticipated need to modify systemic medication known to affect iop (eg, beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers, angiotension converting enzyme inhibitors, and angiotension ii receptor antagonists) during the study period.
utility of perfusion mri to detect radiation necrosis in patients with brain metastases

Conditions: Invasive Malignant Neoplasm; Metastatic Malignant Neoplasm in the Brain

Summary: this trial studies how well dynamic susceptibility contrast-magnetic resonance imaging (mri) works in determining radiation necrosis and tumor progression in participants with cancer that has spread to the brain and are being treated with radiation therapy. diagnostic procedures, such as dynamic susceptibility contrast-mri, may improve the ability to determine indeterminate post-treatment changes seen on imaging after radiation therapy.

primary objective: i. to prospectively determine the sensitivity and specificity of dynamic susceptibility contrast (dsc)-mri parameters in detecting tumor recurrence versus radiation necrosis for brain metastases treated with stereotactic radiosurgery (srs). secondary objectives: i. to correlate radiographic diagnoses with pathologic diagnoses when surgical resection is clinically indicated. ii. to correlate baseline relative cerebral blood volume (rcbv) values and other hemodynamic parameters with tumor primary histology. iii. to assess overall survival, local failure, distant brain failure and neurologic death. outline: participants undergo a diagnostic mri with and without contrast and treatment planning dsc perfusion mri series before receiving srs at 4-6 weeks after srs, and then every 3 months unless clinically indicated sooner.

Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of invasive malignancy with at least radiographic evidence of intracranial disease as seen on mri. * at least one identifiable intracranial lesion ≥ 1 cm in diameter enrolled within 4 weeks of diagnosis. * eastern cooperative oncology group (ecog) performance status ≥ 2. exclusion criteria: * planned whole-brain radiotherapy (wbrt) with boost. * leptomeningeal disease. * inadequate renal function (estimated glomerular filtration rate \[egfr\] \> 30 ml/min/1.73 m²) or contrast allergy. * non-mri compatible pacemaker with pacemaker dependence.
evaluation of the preventing aids through live movement and sound (palms) intervention for minority adolescents

Conditions: HIV Infections

Summary: the purpose of this program evaluation is to determine whether the preventing aids through live movement and sound (palms) group-level intervention is effective in reducing hiv sex risk behaviors and increasing hiv testing of high-risk, incarcerated or adjudicated youth. the intent of this program is to support the evaluation of an existing intervention and provide feedback to the implementing organization for improved program effectiveness, not to conduct research.

philadelphia health management corporation (phmc) is evaluating the preventing aids through live movement and sound (palms) group-level intervention for high-risk, incarcerated or adjudicated youth. palms uses three theater-based sessions to increase knowledge about hiv/aids, increase hiv testing, and reduce risky sexual behavior through increased self-efficacy. the intervention is delivered by peers, and peers work with the intervention team to use evaluation results to improve the program. the evaluation will recruit male adolescents, aged 12 to 18 years, who are residing in juvenile justice or drug treatment facilities in philadelphia. the evaluation design uses concurrent intervention (n=132) and comparison (n=132) groups. data will be collected at baseline, immediate post-intervention, and at a 6-month post-intervention follow-up. the intent of this program is to support the evaluation of an existing intervention and provide feedback to the implementing organization for improved program effectiveness, not to conduct research.

Eligibility criteria:
inclusion criteria: * male adolescents * between the ages of 12 and 18 * receiving residential services at juvenile justice or drug treatment facilities * african-american or latino exclusion criteria: * do not speak english * prior participation in palms intervention * female adolescents

Keywords: adolescent *hiv infections/ pc [prevention & control] male humans risk-taking safe sex sexual behavior hiv hiv seronegativity
phase i dose escalation trial of volasertib in combination with azacitidine in patients with mds or cmml

Conditions: Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic

Summary: to investigate the maximum tolerated dose (mtd), safety, pharmacokinetics, and efficacy of volasertib in combination with azacitidine in patients with myelodysplastic syndromes (mds) or chronic myelomonocytic leukemia (cmml) and not candidates for hematopoietic stem cell transplant


Eligibility criteria:
inclusion criteria: * adult patients with previously untreated, intermediate-2 or high- risk mds or cmml not eligible for hematopoietic stem cell transplantation (hsct) based on documented patients characteristics like age, performance status, concomitant diagnoses, and organ dysfunctions * further inclusion criteria apply exclusion criteria: * prior or concomitant therapy for higher risk mds (for example, but not limited to, hypomethylating agents like azacitidine). note: prior treatment with erythropoetin (epo) is allowed up to \> 1 week before treatment with study medication. patients must have not received mds therapy since diagnosis of higher-risk mds. however, previous lenalidomide treatment could have been administered for lower-risk mds treatment as long as this therapy was discontinued at least \> 4 weeks before initiation of the current study treatment. * treatment with any investigational drug within 2 weeks before first administration of present trial drug or within less than 5 half lives of the investigational drug before treatment with the present trial drug, whichever is longer. * second malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment, e.g. in prostate or breast cancer). * corrected qt interval according to fridericia (qtcf) prolongation \> 470 ms or qt prolongation deemed clinically relevant by the investigator (e.g., congenital long qt syndrome).the qtcf will be calculated as the mean of the 3 electrocardiograms (ecgs) taken at screening. * total bilirubin \> 1.5 x upper limit of normal not related to gilberts disease, hemolysis, or secondary to mds. * aspartate amino transferase (ast) or alanine amino transferase (alt) \> 2.5 x the upper limit of normal (uln) creatinine \> 1.5 x uln * active hepatitis b or hepatitis c, or laboratory evidence for a chronic infection (hepatitis test results done in routine diagnostics are acceptable if done within 14 days before first study treatment dose). * hiv infection (hiv test results in routine diagnostics are acceptable if done within 14 days before first study treatment dose). * severe illness or organ dysfunction involving the kidney, liver or other organ system (e.g. active uncontrolled infection , unstable angina pectoris or history of severe congestive heart failure, clinically unstable cardiac disease or pulmonary disease), which in the opinion of the investigator would interfere with the evaluation of the safety of the study treatment * further exclusion criteria apply
biofeedback for psoriasis

Conditions: Psoriasis; Psoriasis Vulgaris; Psychophysiological Disorder; Anxiety; Depression; Psychological Stress; Physiological Stress; Quality of Life; Skin Disorder; Skin Diseases

Summary: we are conducting a proof-of-concept trial to study the impact of hrv-biofeedback, a mind-body technique designed to improve stress resilience, on the quality of life, mood, and clinical skin severity of patients with psoriasis.

psoriasis is a common, chronic stress-related disease of the skin and joints that is associated with significantly impaired quality of life (qol) and psychological comorbidity, most notably anxiety, depression, and suicidality. the objective of this study is to explore the influence of heart rate variability-biofeedback training (hrv-bf) on measures rating qol, mental health, and clinical severity of psoriasis. we aim to further understand the bidirectional relationship between stress and the skin and to determine whether hrv-bf has the potential to be a beneficial adjuvant therapy for psychocutaneous disorders. a single-arm, proof-of-concept trial will be conducted using a modified, 7-week hrv-bf resiliency protocol at bastyr university california in a small sample of subjects with moderate to severe plaque psoriasis. in order to measure the outcomes of the intervention on the clinical manifestations of psoriasis, we will be administering a set of validated, physician-rated and patient-reported questionnaires, including the psoriasis area and severity index (pasi), dermatology life quality index (dlqi), patient health questionnaire (phq-9), and generalized anxiety disorder (gad-7), in addition to other hrv-bf-specific screening questionnaires to assess whether the subject has any contraindications to this protocol. these assessments will be collected at baseline, end of trial, and at 1-month follow-up for statistical analysis. the goal of this trial is to explore the novel application of hrv-bf for psychocutaneous disorders in order to fill a gap in the provision of evidence-based, integrative services addressing the serious and sometimes fatal psychological impacts of psoriasis.

Eligibility criteria:
inclusion criteria: * at least 18 years old * diagnosed with or are currently experiencing symptoms of psoriasis * located in san diego or within driving distance * have daily access to a smart phone, computer, or tablet * able to read and understand english exclusion criteria: * high risk of suicidality * history of chronic kidney disease * pacemaker * active pregnancy or treatment of cancer or hiv

Keywords: psoriasis anxiety depression biofeedback stress psychophysiological disorder skin disease
a study of delayed and extended release formulation of dextroamphetamine sulfate (hld100) in children with adhd

Conditions: Attention-Deficit Hyperactivity Disorder (ADHD)

Summary: the phase 2 study will evaluate the safety, tolerability and efficacy of hld100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.

this dose-escalation study will examine hld100 in 24 subjects. the subjects (n=24) will be tested with hld100 in ascending doses from 10mg up to 40mg. this study will be divided into several phases: screening, active treatment and follow-up. all visits have a 2 day window to allow for scheduling.

Eligibility criteria:
inclusion criteria: * subjects must have a diagnosis of adhd as defined by dsm-5 criteria with confirmation using the mini international neuropsychiatric interview for children and adolescents (mini-kid). * subjects must demonstrate mild-to-moderate impairment of adhd symptoms and function per the following at screening (v1) and/or baseline (v2): * adhd-rs-iv score at or above the 90th percentile normalized for sex and age in total score and ≥24 at baseline; * cgi-s score ≥4; * subject body weight must be ≥20 kg. * subject must be considered clinically appropriate for treatment with amphetamine and hld100, including prior treatment experience with an amphetamine product, and ability to swallow treatment capsules. exclusion criteria: * history of, or current, medical condition or laboratory result which, in the opinion of the investigator, unfavorably alters the risk-benefit of study participation, may jeopardize subject safety, or may interfere with the satisfactory completion of the study and study-related procedures. * serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other cardiac problems that may place the subject at increased vulnerability to the sympathomimetic effects of a stimulant drug. * history of seizure disorder (except febrile seizures prior to age 5 and with last occurrence at least 1 year prior to study participation), tourette's disorder, or intellectual disability of minor severity or greater (dsm-5 criteria). * history of psychosis, bipolar disorder, anorexia nervosa, bulimia, or suicide attempt. current depression, anxiety, conduct/behavior disorder, substance use disorder, or other psychiatric condition which, in the investigator's opinion, may jeopardize subject safety or may interfere with the satisfactory completion of the study and study-related procedures. * active suicidal ideation as evidenced by an ideation score of 2 or greater on the c-ssrs. * history of severe allergic reaction or intolerance to amphetamine.
local versus general anaesthesia in stapled hemorrhoidectomy

Conditions: Hemorrhoids

Summary: the purpose of this study is to determine whether local or general anaesthesia in stapled hemorrhoidectomy leads to a shorter operation time with a better patient comfort.

hemorrhoids are a frequent disease with the need of surgical intervention in 10-20% of the patients. the stapled hemorrhoidectomy according to longo under general anesthesia (or spinal) is considered standard of care \[1\]. cohort studies show that a pudendal bloc with local anesthesia is safe and efficient \[2-4\]. the majority of procedures are actually performed in private clinics or in an ambulatory setting underlining the importance of economic issues such as procedure time (anesthesia and operation time) and hospital stay. we hypothesize that stapled hemorrhoidectomy under local anaesthesia shortens anaesthesia time and hospital stay and reduces costs with no disadvantages regarding pain, satisfaction and complication rate.

Eligibility criteria:
inclusion criteria: * hemorrhoids grade iii suitable for elective stapled hemorrhoidectomy exclusion criteria: * age \< 18 years * no informed consent * emergency situation * contraindication to either anaesthesia method * patients not speaking french or german. * additional anal pathology (fissure, tumour).

Keywords: anesthesia, longo, mucosectomy, hemorrhoids
hand sanitizer use for herpes simplex virus-1

Conditions: Virus; HSV-1; Herpes Simplex 1; Herpes Simplex Labialis

Summary: the purpose of this pilot study is to determine if the use of purell hand sanitizer alters the duration, level of pain and discomfort during treatment, and the size of the hsv-1 lesion. the duration of an hsv-1 (herpes) lesion is the primary endpoint for this study. size, pain, and discomfort are the secondary endpoints.

the participants will be divided into a control group (10 participants) and treatment group (10 participants) and will be given either the purell hand sanitizer (treatment group) or medical grade mineral oil (control group) to treat the lesion. participants will apply a large drop of the product (purell hand sanitizer or mineral oil) on a q-tip and will hold the q-tip on the lesion for 10 seconds. participants will be instructed to apply a solution to lesion every waking hour for the next 14 days or until lesion has healed. each day the participant will fill out the daily journal. the journal includes a measurement in millimeters of the lesion with graph paper, recorded number of applications for that day, and two visual analog scales- one measuring any discomfort from the lesion and the other recording the pain during the application process. documentation of changes to the lesion will be recorded in a daily journal until the lesion is healed. there are two days that the participants are expected to return to the clinic for re-examination at day three and the last day when the lesion has healed, or the crust has fallen off. pictures of the lesion will taken at these two points in time. the duration the hsv-1 lesion, level of pain and discomfort during treatment, and the size of the hsv-1 lesion will be statistically measured between the control group (mineral oil) and the treatment group (purell hand sanitizer) to determine if there is any statistical difference between the two groups.

Eligibility criteria:
inclusion criteria: for the purpose of this study participants must be: * in the early prodromal stage of an hsv-1 outbreak (less than 24 hours from initial symptom) * have a visible manifestation of a lesion * be 18 years or older * capable of following daily treatment instructions * willing to complete a daily journal * willing to come to the clinic twice for records and pictures during the14 days that the lesion is present or until participant is free of lesion. exclusion criteria: for the purpose of this study participants cannot: * be immunocompromised * be pregnant * have taken any antiviral medication within the last two weeks * have used any creams in the last ten days.

Keywords: virus hsv-1 herpes simplex 1 herpes simplex labialis